

Special Issue

Trends and Future Development in Precision Medicine

Message from the Guest Editor

In this Special Issue, specific areas of focus include, but are not limited to, the following: Precision medicine approaches in complex chronic diseases (Alzheimer's; cancer; obesity; psychiatric disorders; type2 diabetes (T2D, etc.), and rare diseases; Pharmacogenomics/ pharmacogenetics; Epigenetics in health and human diseases; Epigenetic mechanisms in aging and longevity; Sex differences in genomics/epigenomics and complex human diseases; Gene–environment interactions (GxE); Gut microbiota and complex human chronic diseases; Emerging technologies in “omics” disciplines; Systems biology and omics approaches; Multiomics approaches in complex diseases; Polygenic risk score (PRS); Nanomedicine; Nutrigenomics/personalized nutrition; Bioinformatics/big data/data sharing/artificial intelligence (AI) and precision medicine; Precision medicine in emerging countries; Precision medicine and public health; Interdisciplinary and transdisciplinary approaches in precision medicine. Against this backdrop, we welcome and encourage authors to submit original studies, reviews and meta-analyses as well as multi-country collaborative research and interdisciplinary works.


Guest Editor

Dr. Candan Hizel

Centre Hospitalier de L'Universite de Montreal, Montreal, QC, Canada

Deadline for manuscript submissions

31 July 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/199000

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).